Han-Jong Koh, MD
Internal Medicine · Leesburg, VANPI 1619962263
Payments from drug & device makers
Across 82 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$335
- AbbVie$120
- Amgen$118
- Medtronic$86
- AstraZeneca$83
- Astellas Pharma US Inc$81
- plus $609 from 16 others
What the payments were for
- Food & beverage$1,41899%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $335 |
| AbbVie(2 entities) | 5 | $120 |
| Amgen | 7 | $118 |
| Medtronic | 4 | $86 |
| AstraZeneca | 5 | $83 |
| Astellas Pharma US Inc | 5 | $81 |
| Johnson & Johnson | 4 | $71 |
| Boehringer Ingelheim | 4 | $67 |
| Lilly USA, LLC | 3 | $58 |
| GSK | 4 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| Pfizer | 3 | $48 |
| Amarin Pharma, Inc. | 3 | $44 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Abbott | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Merck | 1 | $23 |
| Genentech USA, Inc. | 1 | $20 |
| Bausch Health US, LLC | 1 | $18 |
| Alk-abello, Inc | 1 | $15 |
| Mayne Pharma Commercial LLC | 1 | $14 |
How this compares
$1,432 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 55 | $71,952 |
| OzempicSemaglutide | 50 | $68,059 |
| RybelsusSemaglutide | 19 | $39,805 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $27,883 |
| JardianceEmpagliflozin | 33 | $22,975 |
| XareltoRivaroxaban | 13 | $20,163 |
| JanuviaSitagliptin Phosphate | 15 | $16,890 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $16,171 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $14,789 |
| Repatha SureclickEvolocumab | 18 | $14,694 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $13,551 |
| AmbienZolpidem Tartrate | 12 | $7,612 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,085 |
| PristiqDesvenlafaxine Succinate | 13 | $4,952 |
| Rosuvastatin Calcium | 314 | $4,672 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $335 | $107,86469 claims |
| PfizerEliquis, Pristiq | $48 | $76,90468 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $56 | $47,75770 claims |
| MerckJanuvia, Janumet | $23 | $30,44226 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Ambien | $34 | $23,78327 claims |
| Boehringer IngelheimJardiance | $67 | $22,97533 claims |
| Johnson & JohnsonXarelto | $71 | $20,16313 claims |
| AbbVieSynthroid | $120 | $3,66552 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Leesburg
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
- Sue BrownCharlottesville$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.